文献速递肝病

长期诺氟沙星治疗对晚期肝硬化患者的影响

Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
PubMed 文献 · Gastroenterology · 2018-08-23

在法国18个中心进行的双盲随机对照试验纳入291例未近期使用氟喹诺酮的Child-Pugh C级肝硬化患者,每日一次口服诺氟沙星400 mg或安慰剂6个月。诺氟沙星未降低Kaplan-Meier法估计的6个月死亡率(14.8% vs 19.7%,P=0.21),但竞争风险分析中6个月死亡累积发生率显著低于安慰剂组(亚分布风险比0.59,95%CI 0.35-0.99)。

要点

  • 诺氟沙星未降低Kaplan-Meier法估计的6个月死亡率(14.8% vs 19.7%,P=0.21)。
  • 竞争风险分析中诺氟沙星组6个月死亡累积发生率显著低于安慰剂组(亚分布风险比0.59,95%CI 0.35-0.99)。
  • 诺氟沙星显著降低任何及革兰阴性细菌感染发生率,未增加艰难梭菌或多重耐药菌感染。

核心结论

  • 在未近期使用氟喹诺酮的晚期肝硬化患者中,诺氟沙星未降低Kaplan-Meier法估计的6个月死亡率,但似乎可提高腹水蛋白浓度低患者的生存率。

研究设计与样本

  • 双盲随机对照试验,纳入291例Child-Pugh C级肝硬化且未近期接受氟喹诺酮治疗的患者,2010年4月至2014年11月在法国18个临床中心进行。
  • 患者随机分为诺氟沙星组(n=144,400 mg每日一次)或安慰剂组(n=147,每日一次),疗程6个月;前6个月每月评估,之后第9个月和第12个月评估。
  • 主要结局为6个月死亡率,采用Kaplan-Meier法估计,对自发性细菌性腹膜炎、肝移植或随访失访进行删失。

主要发现

  • Kaplan-Meier法估计的6个月死亡率诺氟沙星组为14.8%,安慰剂组为19.7%(P=0.21)。
  • 在考虑肝移植的竞争风险分析中,诺氟沙星组6个月死亡累积发生率显著低于安慰剂组(亚分布风险比0.59,95%CI 0.35-0.99)。
  • 腹水蛋白浓度<15 g/L患者中诺氟沙星对比安慰剂6个月死亡的亚分布风险比为0.35(95%CI 0.13-0.93),腹水蛋白浓度≥15 g/L患者中为1.39(95%CI 0.42-4.57)。
  • 诺氟沙星显著降低任何及革兰阴性细菌感染发生率,未增加艰难梭菌或多重耐药菌感染。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is debate over the effects of long-term oral fluoroquinolone therapy in patients with advanced cirrhosis. We performed a randomized controlled trial to evaluate the effects of long-term treatment with the fluoroquinolone norfloxacin on survival of patients with cirrhosis. METHODS: We performed a double-blind trial of 291 patients with Child-Pugh class C cirrhosis who had not received recent fluoroquinolone therapy. The study was performed at 18 clinical sites in France from April 2010 through November 2014. Patients were randomly assigned to groups given 400 mg norfloxacin (n = 144) or placebo (n = 147) once daily for 6 months. Patients were evaluated monthly for the first 6 months and at 9 months and 12 months thereafter. The primary outcome was 6-month mortality, estimated by the Kaplan-Meier method, censoring spontaneous bacterial peritonitis, liver transplantation, or loss during follow-up. RESULTS: The Kaplan-Meier estimate for 6-month mortality was 14.8% for patients receiving norfloxacin and 19.7% for patients receiving placebo (P = .21). In competing risk analysis that took liver transplantation into account, the cumulative incidence of death at 6 months was significantly lower in the norfloxacin group than in the placebo group (subdistribution hazard ratio, 0.59; 95% confidence interval, 0.35-0.99). The subdistribution hazard ratio for death at 6 months with norfloxacin vs placebo was 0.35 (95% confidence interval, 0.13-0.93) in patients with ascites fluid protein concentrations <15 g/L and 1.39 (95% confidence interval, 0.42-4.57) in patients with ascites fluid protein concentrations ≥15 g/L. Norfloxacin significantly decreased the incidence of any and Gram-negative bacterial infections without increasing infections caused by Clostridium difficile or multiresistant bacteria. CONCLUSIONS: In a randomized controlled trial of patients with advanced cirrhosis without recent fluoroquinolone therapy, norfloxacin did not reduce 6-month mortality, estimated by the Kaplan-Meier method. Norfloxacin, however, appears to increase survival of patients with low ascites fluid protein concentrations. ClinicalTrials.gov ID: NCT01037959.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Moreau R, Elkrief L, Bureau C, et al. Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology. 2018. PMID: 30144431. doi:10.1053/j.gastro.2018.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。